Sandoz announces deal to commercialise biosimilar ustekinumab in Europe and North America

Betsy Goodfellow | September 11, 2023 | News story | Research and Development Pharmacy, SB17, Sandoz, commercialisation, ustekinumab 

Sandoz has announced that it has entered into a development and commercialisation agreement with Samsung Bioepis, providing Sandoz the exclusive rights to commercialise the biosimilar SB17 ustekinumab in the US, Canada, EEA, Switzerland and the UK.

Further terms of the agreement have not been announced.

The drug’s reference medicine, Stelara, is a monoclonal antibody medication to interleukin (IL)-12/23, indicated for the treatment of autoimmune disorders such as Crohn’s disease, plaque psoriasis, psoriatic arthritis and ulcerative colitis.

Phase 1 results assessing SB17 were presented at the American Academy of Dermatology (AAD) Annual Meeting in March 2023, and demonstrated that the drug matches its reference in terms of pharmacokinetic bioequivalence, safety, tolerability and immunogenicity. Phase 3 clinical study results are expected to be shared at a medical congress later in 2023.

Richard Saynor, CEO of Sandoz, commented: “This deal represents another major step to reinforce our high-value biosimilar pipeline, in line with our plans to become a standalone global leader. It will further strengthen our immunology patient offering and means we now have five potential high-value upcoming biosimilar launches over the next few years.” 

Betsy Goodfellow

Related Content


FDA approves Sandoz’s Tyruko biosimilar to treat relapsing forms of MS

Novartis’ Sandoz has announced that the US Food and Drug Administration (FDA) has approved its …


Sandoz shares positive results from MYLIGHT phase 3 study

Sandoz has announced positive results from the phase 3 MYLIGHT confirmatory efficacy and safety study …

PharmaTher and Vitruvias sign collaboration agreement to commercialise ketamine-based treatment in the US

Specialty pharmaceutical companies, Canadian PharmaTher and US-based Vitruvias, have entered into a commercialisation partnership to …

Latest content